SCHEDULE 13G/A: Soleus Entities Update Beneficial Ownership in Verastem, Inc. to 1.8%

Soleus Capital Management, L.P. and affiliated entities, including Guy Levy, have updated their beneficial ownership in Verastem, Inc. to an aggregate of 1.8% of the common stock as of March 31, 2025.

Summary

• Soleus Capital Management, L.P., along with its affiliated entities Soleus GP, LLC, and Guy Levy, collectively beneficially own 935,819 shares of Verastem, Inc. common stock.
• This aggregate ownership represents 1.8% of Verastem, Inc.'s outstanding common stock.
• The shares are held directly by Soleus Private Equity Fund III, L.P. (343,519 shares, or 0.7%) and Soleus Capital Master Fund, L.P. (592,300 shares, or 1.2%).
• The percentage ownership is calculated based on 51,486,705 shares of Verastem, Inc. common stock outstanding as of March 19, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on March 20, 2025.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a previous disclosure of beneficial ownership.
• The reporting persons disclaim beneficial ownership of these shares for purposes other than determining their obligations under Section 13(d) of the Exchange Act.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Management Comments

• Guy Levy, as Managing Member of the various Soleus entities, certified that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing is a standard disclosure of an institutional investor's passive ownership stake in a publicly traded company, common across all industries. It does not provide specific insights into the biotechnology or pharmaceutical industry trends where Verastem, Inc. operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the stake held by a significant institutional investor group, which can influence perceptions of institutional confidence in the company.

Key Dates

Keywords

Verastem Inc., Soleus Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Equity Stake